GLP 1 Microdosing Chart: Doses and Basics

Microdosing GLP 1 drugs means taking doses below standard FDA approved starting dose or increasing more slowly than recommended titration schedule. Someone microdosing semaglutide might start at 0.125 mg per week instead of 0.25 mg. Someone microdosing tirzepatide might start at 1.0 mg instead of 2.5 mg.

This is not FDAcapproved. There are no clinical trials studying these ultra low doses. The American Diabetes Association has not endorsed microdosing. And as Cleveland Clinic's Dr. Butsch has pointed out, there is uncertainty about both effectiveness and safety of microdosing compounded GLP-1 drugs.

That said, microdosing is happening. Telehealth companies like Noom, Found, and Hims & Hers have launched microdosing programs. Compounding pharmacies provide vials that make sub standard dosing possible. And some obesity medicine specialists use slower than standard titration for patients who are particularly sensitive to side effects.

What does a GLP 1 microdosing schedule look like?

There is no official microdosing chart because these protocols are not standardized. But general approach used by clinicians and telehealth companies follows a pattern of starting below standard dose and escalating more slowly.

For semaglutide, a typical microdosing schedule might look like this. Weeks 1 through 4 at 0.125 mg. Weeks 5 through 8 at 0.25 mg. Weeks 9 through 12 at 0.375 mg. Weeks 13 through 16 at 0.5 mg. Then continuing to increase by 0.25 mg every four to six weeks as tolerated.

Compare that to standard Wegovy schedule, which starts at 0.25 mg and reaches 2.4 mg in about 16 to 20 weeks. A microdosing patient might take six months or more to reach even 1.0 mg.

For tirzepatide, microdosing might start at 1.0 mg or 1.25 mg weekly for four to six weeks before moving to standard starting dose of 2.5 mg. From there, dose increases might happen every six to eight weeks instead of every four.

Some practitioners also split weekly dose into two smaller injections. Instead of one 0.5 mg shot of semaglutide per week, a patient might take 0.25 mg twice per week. The idea is that smaller, more frequent doses create steadier drug levels and fewer GI peaks. This approach is anecdotal. No clinical trial has tested it.

Why do people microdose?

There are three main reasons.

The first is side effects. GI issues like diarrhea, nausea, and vomiting are most common side effects of GLP-1 drugs, and they're worst during dose increases. Some people find even lowest standard dose intolerable. For them, starting below that floor and titrating even more gradually can make difference between staying on medication and quitting.

The second is cost. GLP-1 drugs cost over $1,000 per month without insurance. By using compounded versions and taking lower doses, some people stretch their supply and spend less. A compounded semaglutide vial might cost $150 to $300 per month at microdoses compared to $500 or more at standard doses.

The third is that some people don't want or need maximum weight loss. They want to lose 10 to 15 pounds, quiet food noise, or improve metabolic markers like blood sugar and cholesterol without full appetite shutdown that higher doses produce. For this group, a lower dose may provide enough benefit.

Does microdosing actually work?

The honest answer is: probably for some people, but we don't know for certain.

Before GLP-1 drugs were approved, phase 2 dose finding trials tested a range of doses. Those studies showed that lower doses did produce some weight loss and some blood sugar improvement, just less than higher doses that eventually got approved.

Some clinicians who use microdosing in practice report that patients at 0.25 mg to 0.5 mg of semaglutide often experience reduced appetite and quieter food cravings, even though those doses are below standard maintenance range. A 2025 case series found that patients taking semaglutide or tirzepatide less frequently (every two to four weeks instead of weekly) were able to keep most of their weight off during maintenance.

Emerging clinical observations suggest that staying in 0.25 mg to 0.5 mg range for semaglutide may deliver 60% to 80% of appetite suppressing effect with fewer side effects. But this hasn't been validated in a controlled trial. Individual responses vary widely.

What are risks?

The biggest risk is that you take a dose too low to be effective and spend months without meaningful progress. You're still injecting a medication, still paying for it, and potentially building a false sense of security that "drug is working" when it's not producing clinical benefit.

There's also a pharmacokinetic concern. GLP-1 drugs are designed to maintain a steady level in your bloodstream with weekly dosing. If your dose is too low, drug may clear from your system before your next injection. When you take next dose, you're essentially restarting rather than maintaining a steady state. Dr. Butsch from Cleveland Clinic has noted that when drug disappears from your system faster than intended, you may experience same side effects all over again because there hasn't been a consistent amount of medication in your body.

Compounded medications carry their own risks. They are not FDA approved. The concentration, purity, and sterility of compounded GLP-1 drugs are not guaranteed to same standard as brand name products. The FDA has issued warnings about certain compounding pharmacies producing GLP-1 products that didn't contain correct dose of active ingredient.

If you overshot on a dose and feel like you need to clear drug from your system, our article on how to get Mounjaro out of your system faster covers what is and isn't possible.

Who is microdosing appropriate for?

Your doctor is right person to decide this, not a social media post or a telehealth ad. But in general, patients who are most likely to benefit from a slower-than-standard approach are people who have a history of severe GI sensitivity to medications, people who tried standard GLP-1 dosing and couldn't tolerate even lowest approved dose, and people who need modest metabolic improvement rather than major weight loss.

People who should not microdose include anyone trying to manage type 2 diabetes with a GLP-1 drug (you need effective doses for blood sugar control), anyone getting their GLP-1 from an unregulated source, and anyone adjusting their own dose without medical supervision.

What should you take away from this?

Microdosing is a real practice that some doctors use. It is not fringe, but it is not proven. The evidence base is thin: no randomized controlled trials, no long term safety data at sub standard doses, and no official dosing guidelines from any medical society.

If you're interested in microdosing, safest path is to work with a doctor who has experience prescribing GLP-1 drugs and who can monitor your response with regular follow up. Adjusting your dose on your own, especially with compounded medications, carries real risks that are worth avoiding.